Holen Sie sich die Stockscreener-App
17.52
1.63%
-0.29
Handel nachbörslich:
17.22
-0.30
-1.71%
Schlusskurs vom Vortag:
$17.81
Offen:
$18
24-Stunden-Volumen:
873.19K
Relative Volume:
1.63
Marktkapitalisierung:
$1.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-8.5463
EPS:
-2.05
Netto-Cashflow:
$-138.01M
1W Leistung:
+0.92%
1M Leistung:
-2.88%
6M Leistung:
-15.08%
1J Leistung:
+94.45%
1-Tages-Spanne:
$17.24
$18.07
1-Wochen-Bereich:
$16.50
$18.07
52-Wochen-Spanne:
$8.17
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
When the Price of (KURA) Talks, People Listen - Stock Traders Daily
Kura Oncology to present AML trial data at ASH meeting - Investing.com
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times
Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com
Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
UBS Group Initiates Coverage on Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan
Kura Oncology Enters Oversold Territory (KURA) - Nasdaq
Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts - MarketBeat
An analyst sees good growth prospects for Kura Oncology Inc (KURA) - SETE News
Where are the Opportunities in (KURA) - Stock Traders Daily
Kura downgraded to hold by Stifel, prefers rival Syndax - MSN
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's Why - MarketBeat
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
Kura Oncology (NASDAQ:KURA) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Stifel sees challenges for Kura Oncology stock with delayed launch in AML market - Investing.com UK
Squarepoint Ops LLC Cuts Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Millennium Management LLC Sells 148,734 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Investor’s Toolkit: Key Ratios for Assessing Kura Oncology Inc (KURA)’s Performance - The Dwinnex
Analyzing Kura Oncology Inc (KURA) After Recent Trading Activity - Knox Daily
Dimensional Fund Advisors LP Sells 468,816 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Examining Kura Oncology Inc (KURA) stock is warranted - US Post News
Kura Oncology Inc: Navigating Market Fluctuations with a 1.42B Market Cap - The InvestChronicle
Closing Figures Unveiled: Kura Oncology Inc (KURA) Drop -3.70, Closes at 18.50 - The Dwinnex
It is Poised to be a Bull Market for Kura Oncology Inc (KURA) - SETE News
Kura Oncology Inc [KURA] Stock sold by Insider Bair Teresa Brophy for $57916.0 - Knox Daily
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by American Century Companies Inc. - MarketBeat
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology - The Manila Times
Kura Oncology's SWOT analysis: promising cancer drug stock faces pivotal year - Investing.com India
Armistice Capital LLC Has $48.39 Million Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Profund Advisors LLC Trims Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Affinity Asset Advisors LLC Reduces Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Naval Daver, MDUnleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics - Audacy
Integral Health Asset Management LLC Takes $2.06 Million Position in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Integral Health Asset Management LLC Invests $2.06 Million in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
HighVista Strategies LLC Takes Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Rhumbline Advisers Reduces Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):